粒子線治療の世界市場規模：タイプ別、製品タイプ別、がんタイプ別、地域範囲別および予測

粒子線治療の市場規模と予測

粒子線治療の市場規模は、2024年には12億3,694万米ドルと評価され、2026～2032年にかけてCAGR 9.59%で成長し、2032年には25億7,345万米ドルに達すると予測されます。

粒子線治療は、陽子、中性子、より重いイオン（炭素など）などの荷電粒子を使用してがんを治療する外部ビーム放射線治療の一種です。その最大の利点はブラッグピークです。ブラッグピークは、粒子がそのエネルギーの大部分を一定の深さに沈着させるときに発生し、隣接する健康な組織への害を抑えながら腫瘍を正確に狙い撃ちすることを可能にします。この精度の高さにより、粒子線治療は、従来型光子を用いた治療に抵抗性を示すがんに特に有用です。

さらに、粒子線治療は、脳腫瘍、前立腺がん、小児悪性腫瘍を含むさまざまな疾患の治療に使用されており、標準的な放射線技術よりも副作用が少なく、患者のQOLが高いです。

粒子線治療の世界市場力学

粒子線治療市場を形成している主要市場力学は以下の通りです。

主要市場促進要因

がん罹患率の上昇：世界のがん罹患率の増加は、粒子線治療市場の主要促進要因です。世界保健機関（WHO）によると、がんは世界最大の死因であり、2020年には約1,000万人が死亡すると予測されています。国際がん研究機関（IARC）によると、2020年に世界で新たに発生したがん患者は1,930万人で、2040年には2,840万人に増加すると予想されています。拡大するがんの負担は、粒子線治療のような革新的な治療法に対する需要を生み出しています。粒子線治療は、従来型放射線治療よりも副作用が少ない可能性がある集中治療を記載しています。

粒子線治療の技術的進歩：粒子線治療システムの継続的な技術進歩は、その応用範囲を広げ、市場拡大に拍車をかけています。米国国立がんラボ（NCI）によると、2021年には米国で37の粒子線治療センターが稼働しており、さらに数カ所が建設中または計画段階にあります。Particle Therapy Co-Operative Group（PTCOG）の統計によると、2021年時点で世界全体で103の粒子線治療施設が稼働しており、さらに41が建設中です。このような施設の急速な増加は、粒子線治療システムの普及と技術的成熟度の高まりを反映しています。

ヘルスケア支出の増加：特に先進国におけるヘルスケア支出の増加は、粒子線治療のような革新的ながん治療法の採用を加速させています。経済協力開発機構（OECD）によると、OECD諸国の医療支出は2019年に経済成長率を上回るペースで増加し、平均でGDPの8.8%を占めました。メディケア・メディケイドサービスセンター（CMS）によると、2020年の国民医療支出は9.7％増の4兆1,000億米ドル、1人当たり1万2,530米ドルに達します。このような医療支出の増加は、粒子線治療のような最先端治療への投資を可能にし、市場成長の原動力となっています。

主要課題

高い運営コスト：粒子線治療センターの設立と運営には、サイクロトロンやシンクロトロンなどの先端技術への多額の投資が必要であり、多くのヘルスケア施設にとっては法外に高価です。この経済的障壁により、特に新興国では利用可能な治療センターの数が減少し、この新しい医療への患者のアクセスが制限され、市場全体の成長が阻害されます。

ヘルスケア提供者の限られた認識：粒子線治療の利点があるにもかかわらず、多くの腫瘍医やヘルスケア専門家は、従来型治療に対する粒子線治療の利点を知らないままです。このような認識のギャップは、患者が先進的治療を勧められないため、粒子線治療の代替治療が十分に利用されないという結果を招きます。医療従事者に対する教育とトレーニングを強化することは、採用率を高め、がん治療における患者の転帰を改善するために不可欠です。

主要動向

がんの有病率の増加：粒子線治療のような先進的治療法に対するニーズは、2022年にがんの新規患者数が世界で2,000万人に達すると予想されていることから高まっています。この動向は、悪性腫瘍を効率的に治療しながら健康な組織へのダメージを軽減し、患者の転帰と生活の質を改善する新しい治療法の使用を医療従事者に促しています。

ヘルスケアインフラへの投資の増加：日本や中国を含むアジア太平洋諸国は、より多くの粒子線治療センターを開発するために多額の投資を行っています。このようなインフラ拡充は、対象人口が多く、アンメットニーズが大きい先進的がん治療に対する需要の高まりを支えるために不可欠です。粒子線治療へのアクセスが改善されれば、これらの地域で粒子線治療の普及が加速すると期待されます。

目次

第1章 世界の粒子線治療市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の粒子線治療市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 粒子線治療の世界市場：タイプ別

• 概要
• 重粒子線
• 陽子線治療

第6章 粒子線治療の世界市場：製品別

• 概要
• サイクロトロン
• シンクロトロン
• シンクロサイクロトロン

第7章 粒子線治療の世界市場：がんタイプ別

• 概要
• 小児がん
• 前立腺がん
• 肺がん
• 乳がん

第8章 粒子線治療の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の粒子線治療市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第10章 企業プロファイル

• Accuray Incorporated
• Brainlab
• Elekta AB
• Xstrahl
• Danfysik A/S
• Hitachi Ltd
• Mevion Medical Systems
• IBA Worldwide
• Panacea
• Shinva Medical Instrument Co. Ltd.

第11章 付録

• 関連調査

Particle Therapy Market Size And Forecast

Particle Therapy Market size was valued at USD 1236.94 Million in 2024 and is projected to reach USD 2573.45 Million by 2032, growing at a CAGR of 9.59% from 2026 to 2032.

Particle therapy is a type of external beam radiotherapy that uses charged particles, such as protons, neutrons, or heavier ions (such as carbon), to treat cancer. Its greatest advantage is the Bragg peak, which occurs when particles deposit the majority of their energy at a given depth, allowing for accurate tumor targeting while limiting harm to adjacent healthy tissues. This precision makes particle therapy especially useful for cancers that are resistant to traditional photon-based therapies.

Furthermore, particle therapy is used to treat a variety of diseases, including brain tumors, prostate cancer, and pediatric malignancies, with fewer side effects and a higher quality of life for patients than standard radiation techniques.

Global Particle Therapy Market Dynamics

The key market dynamics that are shaping the Particle Therapy Market include:

Key Market Drivers

Rising Cancer Incidence: The growing prevalence of cancer worldwide is a primary driver of the Particle Therapy Market. According to the World Health Organization (WHO), cancer is the biggest cause of death worldwide, accounting for approximately 10 million deaths in 2020. According to the International Agency for Research on Cancer (IARC), there were 19.3 million new cancer cases worldwide in 2020, with the number expected to climb to 28.4 million by 2040. The expanding cancer burden is generating demand for innovative treatment methods such as particle therapy, which provides focused treatment with possibly fewer side effects than conventional radiotherapy.

Technological Advancements in Particle Therapy: Continuous technological advancements in particle treatment systems are broadening their applications and fueling market expansion. According to the National Cancer Institute (NCI), 37 particle therapy centers were in operation in the United States in 2021, with several more under construction or in the planned stages. According to the Particle Therapy Co-Operative Group (PTCOG) statistics, there were 103 particle therapy facilities in operation globally as of 2021, with an additional 41 under construction. This rapid growth of facilities reflects the increasing adoption and technological maturity of particle therapy systems.

Increasing Healthcare Expenditure: Rising healthcare spending, particularly in industrialized countries, is accelerating the adoption of innovative cancer treatment methods such as particle therapy. According to the Organization for Economic Cooperation and Development (OECD), health spending in OECD countries increased faster than economic growth in 2019, accounting for 8.8% of GDP on average. According to the Centers for Medicare and Medicaid Services (CMS), national health spending increased by 9.7% to USD 4.1 Trillion in 2020, or $12,530 per person. This increased healthcare spending allows for investments in cutting-edge treatments such as particle therapy, which drives market growth.

Key Challenges:

High Operational Costs: Establishing and operating particle therapy centers necessitates significant investment in advanced technology, such as cyclotrons and synchrotrons, which are prohibitively expensive for many healthcare facilities. This financial barrier reduces the number of available treatment centers, particularly in developing countries, limiting patient access to this new medicine and impeding overall market growth.

Limited Awareness among Healthcare Providers: Despite the benefits of particle therapy, many oncologists and healthcare professionals remain unaware of its advantages over traditional treatments. This awareness gap results in the underutilization of particle therapy alternatives, as patients are not recommended for advanced therapies. Increased education and training for healthcare practitioners are critical to increasing adoption rates and improving patient outcomes in cancer treatment.

Key Trends:

Growing Prevalence of Cancer: The need for advanced treatment modalities like particle therapy is growing as the number of new cases of cancer is expected to reach 20 million worldwide in 2022. This trend is encouraging healthcare practitioners to use novel therapies that reduce damage to healthy tissues while efficiently treating malignancies, thereby improving patient outcomes and quality of life.

Increased Investment in Healthcare Infrastructure: Countries in Asia Pacific, including Japan and China, are making significant investments to develop more particle therapy centers. This infrastructure expansion is critical for supporting the growing demand for advanced cancer treatments, which is driven by a large target population and significant unmet clinical needs. Improved access to particle therapy is expected to accelerate its adoption in these regions.

Global Particle Therapy Market Regional Analysis

Here is a more detailed regional analysis of the Particle Therapy Market:

North America:

According to Verified Market Research, North America is estimated to dominate the market during the forecast period. North America, particularly the United States, has a high cancer burden, which drives the desire for sophisticated treatment options such as particle therapy. According to the American Cancer Society's Cancer Facts & Figures 2023, the United States is expected to see 1,958,310 new cancer cases and 609,820 cancer deaths in 2023. The National Cancer Institute estimates that 39.5% of men and women will be diagnosed with cancer at some point in their lives. This high incidence rate is a major driving force behind the region's adoption of novel cancer treatments such as particle therapy.

Furthermore, North America has a robust healthcare research and development ecosystem, which fosters advances in cancer treatment technology. The National Cancer Institute (NCI) states that it got $6.9 billion for cancer research in fiscal year 2022, with a significant portion of that going toward discovering and refining cancer treatment modalities. Also, the Particle Therapy Co-Operative Group (PTCOG) said that as of 2021, 37 particle treatment facilities were in operation in North America, with several more under construction or in the planning phases. This concentration of research funds and infrastructure demonstrates the region's commitment to developing particle therapy methods and treatments.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. The Asia-Pacific region has experienced a huge increase in cancer diagnoses, fueling demand for innovative treatment alternatives such as particle therapy. According to the World Health Organization's International Agency for Research on Cancer (IARC), the Asia-Pacific region accounted for 49.3% of all new cancer cases worldwide in 2020. According to GLOBOCAN 2020 data, there were approximately 9.5 million new cancer cases in Asia in 2020, with the number expected to rise to 14.7 million by 2040. This significant and growing cancer burden is a crucial factor in the region's adoption of novel cancer treatments like particle therapy.

Furthermore, many Asian countries are aggressively promoting the research and application of innovative medical technologies, such as particle therapy. For example, Japan, a leader in particle therapy in Asia, has received major government backing for this technique. According to the Particle Therapy Co-Operative Group (PTCOG), Japan has the most particle therapy facilities in Asia, with 20 operational as of 2021. The Japanese government has designated particle treatment as an "advanced medical technology" and is providing financial assistance for its development and deployment. Similarly, countries such as China and South Korea are rapidly growing their particle therapy capabilities, with official support.

Global Particle Therapy Market: Segmentation Analysis

The Particle Therapy Market is segmented on the basis of Type, Product, and Cancer Type.

Particle Therapy Market, By Type

• Proton Therapy
• Heavy Ion Therapy

Based on Type, the market is segmented into Proton Therapy and Heavy Ion Therapy. The proton therapy segment is estimated to dominate the Particle Therapy Market due to proton therapy's precision targeting capabilities, which enable the effective treatment of many malignancies while minimizing damage to adjacent healthy tissues. Its improved dose distribution and low long-term adverse effects make it especially appealing for pediatric cases and complicated cancers, resulting in widespread acceptance among healthcare providers and patients. As technology advances and treatment delivery improves, proton therapy's position as the top choice in particle therapy is projected to strengthen further.

Particle Therapy Market, By Product

• Cyclotrons
• Synchrotrons
• Synchrocyclotrons

Based on Product, the Particle Therapy Market is segmented into Cyclotrons, Synchrotrons, and Synchrocyclotrons. The cyclotrons segment is estimated to dominate the market over the forecast period. Cyclotrons are critical components of proton therapy systems, producing and accelerating protons to provide targeted radiation to malignancies. Their broad use is driven by their efficacy in treating a variety of malignancies, including pediatric instances and complicated tumors. As healthcare facilities spend more on innovative cancer treatment technologies, the need for cyclotrons is likely to increase, strengthening their market dominance.

Particle Therapy Market, By Cancer Type

• Pediatric Cancer
• Prostate Cancer
• Lung Cancer
• Breast Cancer
• Others

Based on Cancer Type, the market is divided into Pediatric Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, and Others. The pediatric cancer segment is estimated to dominate the global market due to a growing knowledge of children's unique therapeutic demands, which are particularly vulnerable to radiation. Particle therapy's precision reduces damage to surrounding healthy tissues, making it an excellent choice for treating pediatric cancers. As knowledge of the efficacy and safety of particle therapy in younger patients grows, this segment is projected to maintain its market leadership.

Key Players

• The "Particle Therapy Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Accuray Incorporated, Brainlab, Elekta AB, xstrahl, Danfysik A/S, Hitachi Ltd., Mevion Medical Systems, IBA Worldwide, Panacea, and Shinva Medical Instrument Co. Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Particle Therapy Market Recent Developments
• In September 2023, Siemens Healthineers AG showcased breakthrough technology at the American Society for Radiation Oncology (ASTRO) 2023 annual meeting in California, demonstrating their dedication to innovation and improved results.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PARTICLE THERAPY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PARTICLE THERAPY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PARTICLE THERAPY MARKET, BY TYPE

• 5.1 Overview
• 5.2 Heavy Ion
• 5.3 Proton Therapy

6 GLOBAL PARTICLE THERAPY MARKET, BY PRODUCT

• 6.1 Overview
• 6.2 Cyclotrons
• 6.3 Synchrotrons
• 6.4 Synchrocyclotrons

7 GLOBAL PARTICLE THERAPY MARKET, BY CANCER TYPE

• 7.1 Overview
• 7.2 Pediatric Cancer
• 7.3 Prostate Cancer
• 7.4 Lung Cancer
• 7.5 Breast Cancer

8 GLOBAL PARTICLE THERAPY MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL PARTICLE THERAPY MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Accuray Incorporated
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Brainlab
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Elekta AB
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Xstrahl
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Danfysik A/S
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Hitachi Ltd
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Mevion Medical Systems
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 IBA Worldwide
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Panacea
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Shinva Medical Instrument Co. Ltd.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research